Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CEO Jeffrey M. Leiden sold 125,000 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $141.35, for a total value of $17,668,750.00. Following the completion of the transaction, the chief executive officer now owns 237,407 shares in the company, valued at approximately $33,557,479.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Vertex Pharmaceuticals Incorporated (VRTX) opened at $140.91 on Wednesday. Vertex Pharmaceuticals Incorporated has a twelve month low of $71.46 and a twelve month high of $167.85. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $36,319.37, a P/E ratio of 239.35, a price-to-earnings-growth ratio of 3.44 and a beta of 1.58.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The company had revenue of $578.20 million for the quarter, compared to the consensus estimate of $522.07 million. During the same quarter last year, the company posted $0.16 earnings per share. The company’s revenue for the quarter was up 39.7% compared to the same quarter last year. equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current year.

A number of equities analysts recently commented on VRTX shares. Zacks Investment Research downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. DA Davidson started coverage on Vertex Pharmaceuticals in a report on Friday, September 29th. They issued a “buy” rating and a $200.00 price objective on the stock. Jefferies Group restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 22nd. Needham & Company LLC restated a “buy” rating and issued a $195.00 price objective on shares of Vertex Pharmaceuticals in a report on Sunday, September 17th. Finally, BMO Capital Markets restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, September 27th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-four have assigned a buy rating to the company. Vertex Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $173.15.

Hedge funds have recently made changes to their positions in the business. Achmea Investment Management B.V. grew its holdings in Vertex Pharmaceuticals by 68.0% during the second quarter. Achmea Investment Management B.V. now owns 8,668 shares of the pharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 3,507 shares during the last quarter. NorthCoast Asset Management LLC acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter worth $782,000. Delta Lloyd Asset Management N.V. acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter worth $3,285,000. Prudential Financial Inc. grew its stake in shares of Vertex Pharmaceuticals by 12.8% in the second quarter. Prudential Financial Inc. now owns 444,725 shares of the pharmaceutical company’s stock worth $57,312,000 after acquiring an additional 50,350 shares during the last quarter. Finally, Picton Mahoney Asset Management acquired a new stake in shares of Vertex Pharmaceuticals in the third quarter worth $13,077,000. Institutional investors own 93.33% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Jeffrey M. Leiden Sells 125,000 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.watchlistnews.com/jeffrey-m-leiden-sells-125000-shares-of-vertex-pharmaceuticals-incorporated-vrtx-stock/1760489.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.